Visium Asset Management and Morgan Stanley long Dendreon

And according to this article it is not a small stake.

Latta pointed out what is news is that Visium Asset Management in a
Securities and Exchange Commission filing that showed up today at www.sec.gov, has taken a 10 percent stake in Dendreon. That filing from the New York hedge fund is dated February 12th, but it only appeared online today. The delay isn't unusual. And then, coincidentally, just as I was checking out the filing and reaching out to Visium for comment another filing showed up. This one's from Morgan Stanley which reports that as of Dec. 31, 2007 it took a 6.5 percent stake in DNDN.

So these two firms scooped up 16.5% of the outstanding Dendreon shares while everyone else seems to be shorting the crap out of it? Visium seems to be a biotech hedge fund according to their holdings. Also looking at their holdings it seems that a 10% stake in DNDN might be one of their top 5 largest positions as well. That is a big bet on a stock that pretty much is in limbo until they either get an FDA approval or they partner up with a larger firm.